Table 1.
Summary of Human Clinical Trials Using Human Pluripotent Stem Cells.
| Trial Number | Sponsor | Disease | Stem Cell |
Differentiated Cell at Delivery |
Method | Start Date |
End Date |
Phase | Estimated Enrollment |
Status* |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT01217008 | Geron | Subacute thoracic spinal cord injury |
hESC | Oligodendrocyte progenitor cell |
Injection | Oct. 2010 |
Sept. 2013 |
I | 4/10 received transplant |
Suspended |
| NCT02302157 | Asterias Biotherapeutics |
Subacute thoracic spinal cord injury |
hESC | Oligodendrocyte progenitor cell |
Injection | Mar. 2015 |
Jun. 2013 |
I/II | 13 | Active, recruiting |
| NCT01345006 | Ocata Therapeutics |
Stargardt’s Macular Dystrophy |
hESC | Retinal Pigmented Epithelial Cell |
Injection | Apr. 2011 |
Aug. 2015 |
I/II | 16 | Ongoing, but not recruiting |
| NCT01344993 | Ocata Therapeutics |
Dry age- related macular degeneration |
hESC | Retinal Pigmented Epithelial Cell |
Injection | Apr. 2011 |
Sept. 2015 |
I/II | 16 | Ongoing, but not recruiting |
| -- | RIKEN | Wet age- related macular degeneration |
hiPSC | Retinal Pigment Epithelial Cell |
Scaffold implant |
Sept. 2014 |
? | -- | 1 | Active |
| NCT02286089 | Cell Cure Neurosciences, Ltd. |
Dry age- related macular degeneration |
hESC | Retinal Pigment Epithelial Cell |
Scaffold implant |
Apr. 2015 |
Aug. 2017 |
I/II | 15 | Active, recruiting |
| NCT02057900 | Assistance Publique- Hopitaux de Paris |
Heart Failure | hESC | SSEA1+Isl-1+ cardiomyocyte progenitor cell |
Fibrin scaffold implant |
Jun. 2013 |
Jun. 2017 |
I | 6 | Active, recruiting |
| NCT02239354 | ViaCyte | Type I diabetes mellitus |
hESC | Pancreatic progenitor cell (PEC-01) |
Encapsulated subcutaneous implant |
Sept. 2014 |
Aug. 2017 |
I/II | 40 | Active, recruiting |
*
As of August 2015.
hESC: human embryonic stem cell; hiPSC: human induced pluripotent stem cell.